XML 35 R15.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 9 - Commitments | 9 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Leases And Commitments Disclosure [Text Block] | Note 9. Commitments The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company’s obligations under these contracts are largely based on services performed. The Company also had non-cancellable commitments for the manufacture of simufilam's active pharmaceutical ingredient totaling approximately $3.6 million at September 30, 2024.

X
- Definition The entire disclosure regarding leases and commitments. + References No definition available. + Details
Name: | sava_LeasesAndCommitmentsDisclosureTextBlock
Namespace Prefix: | sava_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration